Intrahepatic cholestasis with defective conversion of trihydroxycoprostanic acid to cholic acid is a very rare inherited bile acid synthesis disorder. It is now usually called congenital bile acid synthesis defect type 4 (CBAS4) or AMACR deficiency / alpha-methylacyl-CoA racemase deficiency. In simple words, the liver cannot properly finish an important chemical step that helps make normal bile acids. Because that step fails, abnormal bile acid intermediates, including trihydroxycoprostanic acid, can build up, while normal bile acids such as cholic acid are not made in the right amount. This can reduce bile flow, hurt fat digestion, lower absorption of vitamins A, D, E, and K, and damage the liver. In some people, especially later in life, it can also affect nerves, movement, and vision. [1] [2] [3]
This condition is usually called congenital bile acid synthesis defect type 4 (CBAS4). It is a very rare inherited liver disease, most often linked to AMACR deficiency. In simple words, the liver cannot finish an important bile-acid making step, so normal cholic acid becomes too low and abnormal bile intermediates build up. That can reduce bile flow, injure liver cells, lower fat absorption, and cause low levels of vitamins A, D, E, and K. Some people mainly have liver disease, while others also develop nerve or eye problems.
The most important disease-specific medicine with the strongest evidence is oral cholic acid. The FDA-approved product CHOLBAM is approved for bile acid synthesis disorders due to single enzyme defects, and published long-term studies show that cholic acid replacement can improve bile flow, reduce toxic bile intermediates, and support liver health in many patients when started early and monitored by specialists.
Other names
Other names used for this disorder include CBAS4, congenital bile acid synthesis defect 4, BAS defect type 4, trihydroxycoprostanic acid in bile, and alpha-methylacyl-CoA racemase deficiency. Some papers also describe it under the gene problem name AMACR deficiency. These names point to the same basic disease process: a problem in bile acid formation linked to the AMACR gene. [1] [2] [4]
Types
-
Infantile liver-predominant type
-
Childhood mixed type with liver and nutrition problems
-
Adult neurologic type with nerve and movement problems
-
Mild or atypical type with only abnormal liver tests for some time
-
Familial autosomal recessive type based on inheritance pattern
Doctors do not always divide CBAS4 into fixed official subtypes the way they do for some other diseases. Still, real patients often fall into these practical patterns. Some babies mainly show cholestasis and jaundice. Some children show poor growth and vitamin problems. Some adults show neuropathy, ataxia, seizures, retinopathy, or cognitive decline. This is why the disease is called variable in expression. [1] [3] [5] [6]
Causes
This disease has one main true root cause: a person inherits two harmful AMACR gene changes, one from each parent. To match your requested format, the 20 points below explain the main cause-related genetic patterns and disease mechanisms doctors use when they explain why this disorder happens. [1] [4] [5]
-
Biallelic AMACR gene mutation is the main cause. The child receives two nonworking copies of the gene, so the AMACR enzyme does not work well enough. [1] [4]
-
Autosomal recessive inheritance causes the disease pattern. Parents are often healthy carriers, but a child can become affected if both pass on the altered gene. [1] [4]
-
Homozygous mutation can cause disease, meaning the same harmful gene change is inherited from both parents. [4] [5]
-
Compound heterozygous mutation can also cause disease, meaning the person has two different harmful AMACR changes, one on each copy of the gene. [4] [5]
-
Missense variants may change one amino acid in the enzyme and make it weak or unstable. [4] [5]
-
Nonsense variants may create a stop signal too early, so the body makes a short, broken enzyme. [4] [5]
-
Frameshift variants may disturb the reading frame of the gene, which usually gives a faulty protein. [4] [5]
-
Splice-site variants may stop the gene from being copied into normal messenger RNA, which lowers normal enzyme production. [4] [5]
-
Low AMACR enzyme activity is the direct biochemical cause. Without enough enzyme action, the liver cannot process some bile acid intermediates normally. [1] [4] [7]
-
Defective peroxisomal bile acid side-chain processing contributes to disease. This is an important chemical step in making mature bile acids. [7] [8]
-
Poor conversion of trihydroxycoprostanic acid toward normal bile acids is the classic cause named in the disorder title. [1] [2]
-
Reduced cholic acid production causes weak bile flow and poorer fat handling in the intestine. [2] [8] [9]
-
Accumulation of abnormal bile acid intermediates can injure liver cells and worsen cholestasis. [7] [8]
-
Abnormal handling of branched-chain lipids such as pristanic acid may contribute to neurologic disease in some patients. [5] [6] [4]
-
Carrier parents in the same family line raise risk, especially when both carry a harmful AMACR change. [1] [4]
-
Consanguinity or close parental relation can increase the chance that both parents carry the same rare recessive mutation. This is a risk factor, not the biochemical cause itself. [5] [7]
-
Residual enzyme function differences help explain why one person may present in infancy and another in adulthood. Different mutations can leave different amounts of enzyme activity. [5] [6]
-
Failure to build a normal bile acid pool reduces bile flow and normal digestion, which helps produce cholestasis and malabsorption. [8] [9]
-
Secondary vitamin deficiency from poor fat absorption does not start the gene disease, but it helps explain why symptoms become worse over time. [2] [8]
-
Delayed diagnosis and delayed bile acid replacement therapy do not genetically cause the disorder, but they can strongly worsen liver and nerve injury. [7] [9] [10]
Symptoms
-
Jaundice means yellow skin and yellow eyes. It happens because bile pigments build up in the blood when bile flow is poor. [2] [11]
-
Dark urine can happen because conjugated bilirubin leaves the body through the kidneys. [11] [12]
-
Pale or clay-colored stool may happen when too little bile reaches the intestine. [11] [12]
-
Poor weight gain or failure to thrive is common when fat absorption is poor and the child cannot get enough energy and vitamins. [1] [2]
-
Fat malabsorption means the intestine cannot absorb fats well because normal bile acids are lacking. [1] [2] [8]
-
Steatorrhea means greasy, bulky, foul-smelling stool. This is a common result of fat malabsorption. [2] [8]
-
Hepatomegaly means an enlarged liver. It can happen when abnormal metabolites and cholestasis injure the liver. [1] [7]
-
Easy bruising or bleeding may happen because vitamin K absorption falls when bile acids are low. [8] [11]
-
Bone weakness or rickets-like problems may develop from vitamin D deficiency related to fat malabsorption. [8] [11]
-
Numbness, tingling, or weakness in the limbs can appear when the disease affects peripheral nerves. [3] [5] [6]
-
Ataxia means poor balance and unsteady walking. Some adults with AMACR deficiency develop this neurologic problem. [3] [6]
-
Seizures can occur in some affected adults or older patients. [5] [6]
-
Vision problems or pigmentary retinopathy may appear in the neurologic form of the disease. [6] [13]
-
Cognitive decline or memory problems can happen in later-onset cases with brain involvement. [4] [6]
-
Chronic tiredness may happen from long-term liver disease, poor nutrition, and vitamin deficiency. [2] [8]
Diagnostic tests
Physical exam tests
1. General skin and eye inspection for jaundice is often the first clue. The doctor looks for yellow color in the skin and the white part of the eyes. This simple exam helps show that bilirubin is high and cholestasis may be present. [11] [12]
2. Growth assessment includes weight, height, and head growth in children. Poor growth may suggest long-term malabsorption and chronic liver disease. [1] [2]
3. Abdominal inspection and palpation for hepatomegaly means the doctor looks at and gently feels the belly to check whether the liver is enlarged. This can support liver involvement. [1] [7]
4. Stool and nutrition history review is important. The doctor asks about pale stool, greasy stool, poor feeding, and vitamin deficiency signs. This is simple but very useful in bile acid disorders. [2] [8]
Manual tests
5. Liver palpation is a bedside manual exam. The clinician feels the liver edge under the ribs to check size, tenderness, and texture. It does not confirm the diagnosis alone, but it helps show liver disease. [7] [11]
6. Neurologic bedside motor exam checks muscle power, tone, gait, and coordination. This matters because AMACR deficiency may cause adult-onset neuropathy, ataxia, or weakness. [3] [5] [6]
7. Deep tendon reflex testing is done with a reflex hammer. Abnormal reflexes can support nerve or spinal tract involvement in neurologic cases. [6] [13]
8. Sensory bedside testing checks touch, pain, vibration, and position sense. It helps detect peripheral neuropathy, which has been reported in AMACR deficiency. [3] [6] [13]
Lab and pathological tests
9. Direct and total bilirubin blood test helps confirm cholestasis. In cholestatic disease, direct bilirubin is often raised. [11] [12]
10. Liver enzyme panel usually includes AST, ALT, ALP, and GGT. In bile acid synthesis defects, liver enzymes may be abnormal, and some forms show low or normal serum bile acids or low/normal GGT patterns. [3] [7] [11]
11. Serum bile acid testing is useful, although in some genetic bile acid synthesis defects the total serum bile acids may be low or not as high as expected. That unusual result can be a clue. [3] [11]
12. Urine bile acid profile by mass spectrometry is one of the most important tests. It can detect abnormal bile acid intermediates and strongly suggest an inborn error of bile acid synthesis. [7] [10] [14]
13. Plasma or serum pristanic acid level may be increased in AMACR deficiency and can help support the diagnosis, especially in neurologic forms. [5] [6] [4]
14. Pristanic acid to phytanic acid ratio may also support the biochemical diagnosis in some patients. [5] [6]
15. Fat-soluble vitamin levels such as vitamins A, D, E, and K help show whether malabsorption has caused nutritional damage. [8] [11]
16. Coagulation tests, such as PT/INR help assess liver synthetic function and vitamin K deficiency. A long PT/INR may suggest serious disease or poor vitamin absorption. [11] [12]
17. Genetic testing of the AMACR gene is the key confirmatory test. Finding two disease-causing variants confirms the molecular diagnosis in the right clinical setting. [1] [4] [7]
18. Liver biopsy and pathology may be used when the diagnosis is unclear. It can show cholestatic liver injury and help rule out other diseases, although biopsy alone cannot specifically prove AMACR deficiency. [7] [14]
Electrodiagnostic tests
19. Nerve conduction studies and electromyography are useful if the patient has weakness, numbness, gait problems, or suspected neuropathy. They help measure how well nerves and muscles are working. [3] [6] [13]
Imaging tests
20. Abdominal ultrasound is often the first imaging study in cholestasis. It helps look at liver size, bile ducts, gallbladder, and other causes of jaundice. In neurologic cases, doctors may also add brain MRI if there are seizures, balance problems, or cognitive decline, but ultrasound remains the main first liver imaging test. [11] [12] [14]
Non-Pharmacological Treatments
1. Specialist follow-up. Regular follow-up with a liver and metabolic team helps catch worsening jaundice, poor growth, vitamin deficiency, and liver scarring early. The purpose is early correction. The mechanism is simple: frequent review leads to fast testing, fast dose changes, and safer long-term care.
2. Nutrition assessment. A dietitian should review calories, protein, fat tolerance, stools, and growth. The purpose is to prevent malnutrition. The mechanism is better matching of food intake to poor bile flow and poor fat absorption.
3. Growth monitoring. Weight, height, head growth in infants, and body mass tracking are important. The purpose is to detect failure to thrive. The mechanism is early recognition of energy deficit caused by cholestasis and fat malabsorption.
4. Fat-soluble vitamin monitoring. Blood testing for vitamins A, D, E, and K is a key non-drug management step. The purpose is to prevent blindness, bone disease, nerve injury, and bleeding. The mechanism is early detection of malabsorption-related deficiency.
5. Genetic counseling. Families benefit from counseling because this is usually an inherited disorder. The purpose is to explain recurrence risk and family testing. The mechanism is clearer reproductive planning and earlier testing in siblings.
6. Urine and blood metabolite follow-up. Specialized bile-acid testing can show whether toxic intermediates are falling. The purpose is treatment monitoring. The mechanism is direct measurement of disease activity rather than guessing from symptoms alone.
7. Liver function monitoring. Repeated bilirubin, AST, ALT, GGT, INR, and albumin checks are essential. The purpose is to watch safety and disease control. The mechanism is early detection of inflammation, worsening synthetic function, and treatment failure.
8. Ultrasound surveillance. Liver and spleen ultrasound can help detect cirrhosis, portal hypertension, or other complications. The purpose is complication screening. The mechanism is noninvasive imaging of liver structure and blood-flow-related changes.
9. Stool and fat absorption review. Pale stool, greasy stool, and diarrhea should be followed carefully. The purpose is to measure how badly digestion is affected. The mechanism is bedside assessment of bile-dependent fat absorption.
10. Adequate calories. Many patients need higher-calorie meals. The purpose is to protect growth and muscle mass. The mechanism is replacing calories lost because digestion and absorption are inefficient.
11. Medium-chain triglyceride–focused diet planning. MCT-containing nutrition is often used in cholestatic disease because it is easier to absorb than long-chain fat. The purpose is better energy intake. The mechanism is less dependence on normal bile micelle formation.
12. Hydration support. Good fluid intake helps children and adults who have poor feeding, vomiting, or diarrhea. The purpose is circulation and kidney protection. The mechanism is prevention of dehydration during illness or reduced intake.
13. Skin care for itching. Cool baths, fragrance-free moisturizer, trimmed nails, and cotton clothing can reduce skin injury from scratching. The purpose is comfort and infection prevention. The mechanism is lowering irritation and skin barrier damage.
14. Bone health support. Safe sunlight exposure, weight-bearing activity when possible, and monitoring of bone pain are useful. The purpose is to reduce weak bones from long cholestasis and vitamin D deficiency. The mechanism is support of bone remodeling and early detection of bone disease.
15. Eye assessment. Vision review may be needed because vitamin A deficiency and some CBAS4 cases can involve eye problems. The purpose is early protection of sight. The mechanism is early correction of nutritional or neurologic complications.
16. Neurology review. Some patients develop neuropathy, seizures, or developmental problems. The purpose is early support and rehabilitation. The mechanism is faster diagnosis of extrahepatic disease linked to AMACR deficiency.
17. Physical therapy. When weakness or neuropathy appears, guided exercise can help mobility and balance. The purpose is function preservation. The mechanism is strengthening muscles and preventing contractures or deconditioning.
18. Infection prevention. Good hand hygiene, food safety, and timely vaccines are helpful because liver disease and malnutrition raise risk. The purpose is fewer infections. The mechanism is lowering exposure during a time of reduced physiologic reserve.
19. Early transplant evaluation when needed. If liver function keeps worsening despite therapy, transplant referral should not be delayed. The purpose is survival and better long-term liver function. The mechanism is replacing a failing liver before severe decompensation develops.
20. Family education. Teaching families about jaundice, bleeding, pale stool, confusion, swelling, and poor feeding is part of treatment. The purpose is faster emergency response. The mechanism is earlier recognition of danger signs at home.
Drug Treatments
1. Cholic acid. This is the main disease-directed drug. FDA labeling states that CHOLBAM is indicated for bile acid synthesis disorders due to single enzyme defects. The usual dose is 10 to 15 mg/kg/day taken orally, either once daily or in divided doses, and it should be adjusted by specialist monitoring. Its purpose is to replace missing primary bile acid. Its mechanism is suppression of abnormal bile-acid production and improvement of bile flow. Main side effects can include diarrhea, reflux, malaise, skin problems, and worsening liver tests in some patients.
2. Ursodiol. Ursodiol is sometimes used in cholestatic disease support, although it is not the disease-specific FDA-approved therapy for CBAS4. It can help bile flow in selected patients, but it does not replace the missing primary bile acid the way cholic acid does. Purpose: supportive cholestasis care. Mechanism: a more hydrophilic bile acid pool and altered bile composition. Side effects may include diarrhea and abdominal upset. Dosing is individualized by the treating specialist.
3. Phytonadione (vitamin K1). Vitamin K is used when cholestasis causes poor absorption and bleeding risk. Purpose: support normal clotting. Mechanism: replacement of a vitamin needed to activate clotting factors. Dose depends on age, laboratory results, and route. Side effects are usually limited, but dosing must be supervised because bleeding disorders in liver disease can be complex.
4. Vitamin A replacement. This is used when deficiency affects vision, immunity, growth, or epithelial health. Purpose: correct malabsorption-related deficiency. Mechanism: restoration of retinoid-dependent cell and eye function. Dose must be individualized because too much vitamin A can be toxic, especially in liver disease.
5. Vitamin D replacement. This is often needed because chronic cholestasis reduces fat absorption and harms bone health. Purpose: support calcium balance and bones. Mechanism: improved intestinal calcium handling and bone mineralization. Dose is based on age and blood levels. Too much can cause hypercalcemia, so follow-up testing is important.
6. Vitamin E replacement. Vitamin E deficiency can contribute to neurologic injury and oxidative stress. Purpose: protect nerves and cells. Mechanism: antioxidant activity. Dosing is individualized, especially in children with cholestasis. Very high doses may raise bleeding risk, especially when vitamin K status is low.
7. Zinc. Zinc may be used when poor intake, diarrhea, or malabsorption causes deficiency. Purpose: help growth, wound healing, and immune function. Mechanism: support of enzyme activity, DNA synthesis, and immune cell function. Excess zinc can cause nausea or copper imbalance.
8. Cholestyramine. This may be used for severe itching in cholestatic conditions. Purpose: reduce pruritus. Mechanism: bile-acid binding in the gut, which can reduce itching signals in some patients. It can also interfere with absorption of other medicines and vitamins, so timing matters.
9. Rifampin. Rifampin is another supportive option sometimes used for cholestatic itch under specialist care. Purpose: reduce refractory pruritus. Mechanism: likely changes in bile acid and itch-related pathways. It can interact with many medicines and may affect liver tests, so close monitoring is needed.
10. Lactulose. Lactulose is not a treatment for CBAS4 itself, but it may be used if advanced liver disease causes hepatic encephalopathy. Purpose: lower ammonia-related confusion. Mechanism: acidification of gut contents and trapping of ammonia in the bowel. Dose is individualized to stool effect.
11. Spironolactone and 12. furosemide. These are supportive diuretics when cirrhosis leads to fluid retention or ascites. Purpose: reduce swelling and belly fluid. Mechanism: increased salt and water loss. Dosing is individualized and requires monitoring of kidney function, blood pressure, and electrolytes.
13. Tacrolimus, 14. mycophenolate mofetil, and 15. prednisone. These are not immune boosters and not primary treatment for CBAS4. They are immune-suppressing drugs commonly used after liver transplantation to protect the new liver. Their purpose is graft survival. Their mechanism is lowering immune attack on the transplanted organ. Side effects can include infection risk, kidney injury, high blood sugar, high blood pressure, stomach upset, and bone problems depending on the drug.
Important honesty note. I cannot truthfully name 20 FDA-proven drugs that specifically treat this rare disease, because current strong disease-specific evidence mainly supports cholic acid, while many other medicines are only supportive or used for complications. There are also no established FDA-approved stem-cell or regenerative drugs for CBAS4 itself at this time.
Dietary Molecular Supplements
Vitamin A, D, E, and K are the most important supplement group because cholestasis commonly causes deficiency of these fat-soluble vitamins. In very simple words, bile is needed to absorb them well, and when bile flow is poor, these vitamins can fall. Vitamin A supports vision and immunity, vitamin D supports bones, vitamin E helps protect nerves and cells, and vitamin K helps blood clot. Doses must be individualized by age, blood level, and liver status.
Other commonly considered supplements are zinc, selenium, and omega-3 fatty acids when intake is poor or deficiency is suspected. Zinc supports growth and immune function. Selenium supports antioxidant systems and thyroid-related biology. Omega-3 fats support cell membranes and nutrition, though they are not a disease cure. Doses depend on age, food intake, lab data, and clinician judgment.
Procedures or Surgeries
1. Liver transplantation is the main major surgery when medical treatment fails or end-stage liver disease develops. It is done to replace a badly damaged liver and restore liver function.
2. Liver biopsy may be done when diagnosis or severity is unclear. It is not a cure, but it helps show inflammation, fibrosis, giant cell change, or cirrhosis and can guide treatment decisions.
3. Gastrostomy tube placement may be used in children with poor growth and prolonged feeding difficulty. It is done to improve nutrition when oral feeding is not enough.
4. Endoscopy with variceal treatment may be needed if portal hypertension leads to varices and bleeding risk. It is done to prevent or control bleeding.
5. Ascites drainage or shunt-type procedures can be used in advanced liver disease with severe fluid problems. These are done only in selected patients for symptom relief or bridge care.
Prevention, Doctor Visit, Food, and Avoidance
Because this is a genetic disease, you usually cannot fully prevent the mutation itself. What you can prevent is late diagnosis and some complications. The best prevention steps are early family testing, early specialist review, regular liver tests, vitamin monitoring, nutrition support, vaccine updates, avoiding alcohol, avoiding unnecessary liver-toxic drugs, quick care during infections, and early transplant referral when the liver worsens.
See a doctor urgently for yellow eyes, dark urine, pale stool, poor weight gain, repeated vomiting, easy bruising, bleeding, severe itching, belly swelling, confusion, seizures, fever, or sudden worsening of jaundice. These can mean worsening cholestasis, vitamin deficiency, infection, or liver failure.
Helpful foods often include energy-dense meals, MCT-containing nutrition if prescribed, lean protein, eggs if tolerated, fortified foods, vegetables, fruits, and foods rich in vitamins and minerals. Foods to limit or avoid usually include alcohol, very greasy meals if they worsen steatorrhea, crash diets, unmonitored herbal products, and unnecessary supplements in high doses, especially fat-soluble vitamins without medical guidance.
FAQs
1. Is this disease rare? Yes, it is very rare.
2. Is it inherited? Usually yes, in an autosomal recessive pattern.
3. What is the main problem? The liver cannot make normal bile acids properly.
4. What is the best disease-specific drug? Oral cholic acid.
5. Can it cause jaundice? Yes.
6. Can it cause poor growth? Yes, because fat absorption can be poor.
7. Why are vitamins low? Because cholestasis reduces absorption of fat-soluble vitamins.
8. Can it affect nerves? Yes, in some patients.
9. Can it affect eyes? Yes, in some patients.
10. Is ursodiol the main approved drug? No. Cholic acid is the FDA-approved disease-directed drug for bile acid synthesis defects due to single enzyme defects.
11. Is there a cure? Some patients improve a lot with cholic acid, but severe disease may still progress.
12. Can a liver transplant help? Yes, when liver failure or major complications develop.
13. Are stem-cell drugs standard? No, not for CBAS4 at present.
14. Should families get counseling? Yes, genetic counseling is helpful.
15. Is early diagnosis important? Very much, because earlier treatment can improve outcomes.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: March 12, 2025.
